Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL892401 | 0.89 | MEN1 (0.77) | MEN1PABPC1KMT2ACA12CA1 | |
| Hydrochloric Acid SCHEMBL1335355 | 0.87 | MEN1 (0.75) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL5353245 | 0.87 | MEN1 (0.75) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL3739 | 0.86 | MEN1 (1.00) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL3270220 | 0.86 | MEN1 (1.00) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL891470 | 0.86 | MEN1 (0.73) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL18034974 | 0.85 | MEN1 (0.68) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL3784250 | 0.84 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL4746638 | 0.84 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL1534013 | 0.84 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124462-A9 | SUBSTITUTED IMIDAZO[5,1-d][1,2,3,5]TETRAZINES FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-04-18 | — | — | US | claimed |
| US-20230183252-A1 | SUBSTITUTED IMIDAZO[5,1-d][1,2,3,5]TETRAZINES FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-06-15 | — | — | US | claimed |
| CN-113271939-B | Imidazole tetrazine compounds | 伊利诺伊大学董事会 | 2025-03-07 | — | — | CN | disclosed |
| US-12234240-B2 | Substituted imidazo[5,1-d][1,2,3,5]tetrazines for the treatment of cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-02-25 | — | — | US | disclosed |
| US-20240124462-A9 | SUBSTITUTED IMIDAZO[5,1-d][1,2,3,5]TETRAZINES FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-04-18 | — | — | US | disclosed |
| US-20230303577-A1 | TEMOZOLOMIDE ANALOGS AND METHODS OF USE | ST. JOHN'S CANCER INSTITUTE (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230183252-A1 | SUBSTITUTED IMIDAZO[5,1-d][1,2,3,5]TETRAZINES FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183252-A1 | SUBSTITUTED IMIDAZO[5,1-d][1,2,3,5]TETRAZINES FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183252-A1 | SUBSTITUTED IMIDAZO[5,1-d][1,2,3,5]TETRAZINES FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230167120-A1 | ARYL-FUSED ISOSELENAZOLE COMPOUND CONTAINING TETRAZINE SUBSTITUENT, SYNTHESIS METHOD THEREFOR, AND USE THEREOF | KEAISE MEDICINE WUHAN CORP. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230141718-A1 | METHODS OF TREATING GLIOBLASTOMA | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-8785371-B2 | Drug delivery of temozolomide for systemic based treatment of cancer | CEDARS-SINAI MEDICAL CENTER (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140161762-A1 | DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140161762-A1 | DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140080783-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATMENT OF SPECIFIC CANCERS | ARDEA BIOSCIENCES, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8673876-B2 | Pharmaceutical combinations for treatment of specific cancers | ARDEA BIOSCIENCES INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130012706-A1 | Methods and Intermediates for the Synthesis of 4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazines | PHARMINOX LIMITED (GB) | 2013-01-10 | — | — | US | disclosed |
| US-20120328555-A1 | DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120071435-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING FOR THE TREATMENT OF SPECIFIC CANCERS | ARDEA BIOSCIENCES, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-7173021-B2 | Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers | TIANJIN NORTH PHARM SCI-TECH CO., LTD. (CN) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183252-A1 | SUBSTITUTED IMIDAZO[5,1-d][1,2,3,5]TETRAZINES FOR THE TREATMENT OF CANCER | MCL1, IDH1, IDH2 | MEN1 186/4885PABPC1 4308/4885KMT2A 453/4885 |
| US-20130012706-A1 | Methods and Intermediates for the Synthesis of 4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazines | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA6, TALDO1 | MEN1 216/4885PABPC1 4575/4885KMT2A 327/4885 |
| US-20230167120-A1 | ARYL-FUSED ISOSELENAZOLE COMPOUND CONTAINING TETRAZINE SUBSTITUENT, SYNTHESIS METHOD THEREFOR, AND USE THEREOF | TXNRD1, TXNRD3, TXNRD2 | MEN1 2432/4885PABPC1 4046/4885KMT2A 1921/4885 |
| US-20120328555-A1 | DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER | TFRC, MET, LIFR | MEN1 2166/4885PABPC1 2773/4885KMT2A 487/4885 |
| US-20140161762-A1 | DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER | TFRC, MET, LIFR | MEN1 2166/4885PABPC1 2773/4885KMT2A 487/4885 |
| US-20240124462-A9 | SUBSTITUTED IMIDAZO[5,1-d][1,2,3,5]TETRAZINES FOR THE TREATMENT OF CANCER | MCL1, IDH1, IDH2 | MEN1 186/4885PABPC1 4308/4885KMT2A 453/4885 |
| US-12234240-B2 | Substituted imidazo[5,1-d][1,2,3,5]tetrazines for the treatment of cancer | MCL1, IDH1, IDH2 | MEN1 186/4885PABPC1 4308/4885KMT2A 453/4885 |
| US-20120071435-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING FOR THE TREATMENT OF SPECIFIC CANCERS | TP53, KRAS, PAICS | MEN1 136/4885PABPC1 1831/4885KMT2A 2067/4885 |
| US-20230141718-A1 | METHODS OF TREATING GLIOBLASTOMA | MGMT, ELAVL3, IDH3B | MEN1 1141/4885PABPC1 2204/4885KMT2A 458/4885 |
| US-20230303577-A1 | TEMOZOLOMIDE ANALOGS AND METHODS OF USE | MGMT, TOP2B, IDH3B | MEN1 882/4885PABPC1 2801/4885KMT2A 524/4885 |
| US-20140080783-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATMENT OF SPECIFIC CANCERS | TP53, KRAS, PAICS | MEN1 163/4885PABPC1 2174/4885KMT2A 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.